open access

Ahead of print
Review Papers
Published online: 2019-07-02
Get Citation

Acetylsalicylic acid AD 2019 - known benefits, new challanges

Filip Pawliczak, Jarosław Damian Kasprzak
DOI: 10.5603/FC.a2019.0084

open access

Ahead of print
Review Papers
Published online: 2019-07-02

Abstract

In this paper we present the full summary of present guidelines on antiplatelet properties and indications for prophylactic usage of acetylisalicylic acid. We conclude the results of latest research mainly on primary prevention, optimal dosage in the context of aspirin resistance and possibilities of long-term cooperation with patients requiring acetylsalicylic acid administration. We also discuss prevention methods of frequently occurring gastrointestinal symptoms of drug intolerance.

Abstract

In this paper we present the full summary of present guidelines on antiplatelet properties and indications for prophylactic usage of acetylisalicylic acid. We conclude the results of latest research mainly on primary prevention, optimal dosage in the context of aspirin resistance and possibilities of long-term cooperation with patients requiring acetylsalicylic acid administration. We also discuss prevention methods of frequently occurring gastrointestinal symptoms of drug intolerance.

Get Citation

Keywords

Acetylsalicylic acid; ASA; atherosclerosis; prevention; antiplatelet; pharmacotherapy; ischaemic heart disease; coronary artery disease; ACS; aspirin; side effects; safety profile

About this article
Title

Acetylsalicylic acid AD 2019 - known benefits, new challanges

Journal

Folia Cardiologica

Issue

Ahead of print

Published online

2019-07-02

DOI

10.5603/FC.a2019.0084

Keywords

Acetylsalicylic acid
ASA
atherosclerosis
prevention
antiplatelet
pharmacotherapy
ischaemic heart disease
coronary artery disease
ACS
aspirin
side effects
safety profile

Authors

Filip Pawliczak
Jarosław Damian Kasprzak

References (22)
  1. WHO model list of essential medicines. 20th list, amended August 2017. http://www.who.int/medicines/publications/essentialmedicines/en/.
  2. Lotrionte M, Biasucci LM, Peruzzi M, et al. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis. Prog Cardiovasc Dis. 2016; 58(5): 495–504.
  3. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018; 392(10145): 387–399.
  4. Piepoli M, Hoes A, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016; 37(29): 2315–2381.
  5. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849–1860.
  6. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39: 213–260.
  7. Mahmoud AN, Gad MM, Elgendy AY, et al. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019; 40(7): 607–617.
  8. Bibbins-Domingo K. U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164(12): 836–845.
  9. Bowman L, Mafham M, Wallendszus K, et al. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018; 379(16): 1529–1539.
  10. Gaziano JM, Brotons C, Coppolecchia R, et al. ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018; 392(10152): 1036–1046.
  11. McNeil JJ, Woods RL, Nelson MR, et al. ASPREE Investigator Group, ASPREE Investigator Group. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018; 379(16): 1519–1528.
  12. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994; 25(12): 2331–2336.
  13. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41(6): 961–965.
  14. Dominiak M, Wcisło T, Krzemińska-Pakuła M, et al. Predictors of successful acetylsalicylic acid resistance suppression after percutaneous coronary revascularisation. Kardiol Pol. 2013; 71(12): 1229–1236.
  15. Neubauer H, Kaiser AFC, Endres HG, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011; 9: 3.
  16. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940–2948.
  17. Moberg C, Naesdal J, Svedberg LE, et al. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. Patient. 2011; 4(2): 103–113.
  18. Bhatt DL, Grosser T, Dong JF, et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017; 69(6): 603–612.
  19. Grosser T, Fries S, Lawson JA, et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013; 127(3): 377–385.
  20. Murtaza G, Karim S, Najam-ul-Haq M, et al. Acta Pol Pharm. 2014; 71: 139–143.
  21. Müller P, Dammann HG, Bergdolt H, et al. [The effect of glycine on the gastroduodenal tolerability of acetylsalicylic acid. An endoscopic, controlled double-blind study in healthy subjects]. Arzneimittelforschung. 1991; 41(8): 812–814.
  22. Kusche W, Paxinos R, Haselmann J, et al. Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy: results of a noninterventional trial. Adv Ther. 2003; 20(5): 237–245.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl